Impact of terminal heat sterilization on the quality of peritoneal dialysis solutions

Blood Purification

Volumn 15, Issue 1, 1997, Pages 54-60

  Martis, Leo ^a   Henderson, Lee W ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Biocompatibility; Dialysate; Sterilization

Indexed keywords

PERITONEAL DIALYSIS FLUID;

ARTICLE; BIOCOMPATIBILITY; HEAT TREATMENT; INSTRUMENT STERILIZATION; KIDNEY FAILURE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; ULTRAFILTRATION;

ABDOMINAL PAIN; CYTOKINES; EVALUATION STUDIES; GLUCOSE; HEAT; HEMODIALYSIS SOLUTIONS; HUMANS; HYDROGEN-ION CONCENTRATION; MICROCIRCULATION; PERITONEAL DIALYSIS; PERITONEUM; PHAGOCYTOSIS; STERILIZATION;

EID: 0030887347     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000170317     Document Type: Article

References (44)

1. Use of aseptic processing and terminal sterilization in the preparation of sterile pharmaceuticals for human and veterinary use. Federal Register 1991:58(198):51354-51358.
2. Barr DB: FDA's aseptic processing: Proposed regulation. J Parenter Sci Tcchnol 1993;47:57-59.
3. Taylor RB., Jappy BM., Neil JM: Kinetics of dextrose degradation under autoclaving conditions. J Pharm Pharmacol 1971;23:121-129.
4. Hung CT. Selkirk AB. Taylor RB: A chromatographic quality control procedure based on HPIX-for 5-hvdroxymethylfurfural in autoclaved -glucose infusion fluids. J Clin Hosp Pharm 1982:7:17-23.
5. Cook AP., Macieod TM., Appleton JD, Fell AF: Reversed-phasc high-performance liquid chromatographic method for the quanitation of 5-hydroxvmethytfurfural as the major degradation product of glucose in infusion fluids. Chromosoma 1989: 21:395-401.
6. Henderson IS. Gokal R: Loss of ultrafiltration: in Gokal R (ed): Continuous Ambulatory Peritoneal Dialysis. London. Churchill Livingstone 1986. pp 218-227.
7. Durham DG. I lung CT. Taylor RB: Identification of some acids produced during autoclaving of -glucose solutions using HP1.C. Int J Pharm 1982:11:31-40.
8. Nilsson-Thorell CB., Mascalu N., Andrén AHG., Kjellstrand PIT, Wicslander AP: Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes. Périt Dial Int 1993:13:208-213.
9. Lenderson IS. Couper IA. Lumsdcn A: Potentially irritant glucose metabolites in unused CAPD fluid: In Maher J. Winchester JF (eds): Frontiers in Peritoneal Dialysis. New York. Field. Rich & Associates. Inc. 1985. pp 261-264.
10. Wicslander AP. Nordin MK. Kjellstrand PTT. Boberg UC: Toxicity of peritoneal dialysis fluids on cultured fibroblasts. L-929. Kidney Int 1991: 40:77-79.
11. Wicslander AP. Nordin MK. Martinson E. Kjellstrand PIT. Boberg UC: Heat-sterilized PD fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes. Clin Nephrol 1993; 39:343-348.
12. Rogamgnoni M, Beccari M, Faiolo S., Granello E., Scalia P., Paleardi F: Abdominal pain with infusion of the peritoneal dialysis solutions relieved by alkalization. Peril Dial Bull 1984: 4:188-189.
13. Bunchman TE. Ballal SH: Treatment of inflow pain by pH adjustment of dialysate in peritoneal dialysis. Peril Dial Int 1991:11:179-180.
14. Duwe AK, Vas SI. Weatherhead JW: Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis and bacterial activity in vitro. Infect Immunol 1981:33:130-135.
15. Yamamoto T, Sakakura T, Yamaka-wa M., Horiuchi N, Hirata S., Iritani Y., Nishitani II., Kim M, Kishimoto T, C'hiku T, Matsumoto T., Horio T: Clinical effects of long-term use of neutralized dialysate for continuous ambulatory peritoneal dialysis. Nephron 1992:60:324-329.
16. Topley N. Alobaidi HMM. Davies M. Coles GA. Williams JD. Lloyd D: The effect of dialysate on peritoneal phagocyte oxidative metabolism. Kidney Int 1988:34:404-411.
17. Gordon DL., Rice JL, Avery VM: Surface phagocytosis and host defence in the peritoneal cavity during continuous ambulatory peritoneal dialysis. Eur J Clin Microbial Infect Dis 1990:9:191-197.
18. Yu AW., Zhou XJ., Nawab ZM, Gandhi VC., Ing TS., Vaziri ND: Neutrophilic peritoneal dialysis solutions. Int.J Artif Organs 1992:15: 661-665.
19. Chaimovitz C, Rapoport J., Konforti A., Douvdevani A: Commercial dialysis fluid causes intracellular acidosis in peritoneal macrophages. J Am Soc Nephrol 1992:3:407.
20. Rotstein OD, Nasmith PE., Grin-stein S: The bactcroids by-product succinic acid inhibits neutrophil respiratory burst by reducing intracellular pH. Infect Immun 1987:55: 864-870.
21. Manahan FJ., Ing BL., Chan JC., Gupta DK., Zhou FQ, Pal I, Raha-man MA: Effects of bicarbonate-containing versus lactate-containing peritoneal dialysis solutions on su-peroxide production by human neutrophils. Art if Organs 1989:13:495-497.
22. Liberck T. Topley N, Jorres A. Peterson MM, Coles GA, Gahl GM. Williams JD: Peritoneal dialysis fluid inhibition of polymorphonuclear leucocyte respiratory burst activation is related to the lowering of intracellular pH. Nephron 1993:65: 260-265.
23. Alobaidi HM. Coles CA. Davies M. Lloyd D: Host defence in continuous ambulatory peritoneal dialysis: The effect of the dialysate on phagocytic function. Nephrol Dial Transplant 1986:1:16-21.
24. Van Bronswijk M., Verbrugh HA., Heezius HCJM, van der Meulen J., Oc I.P: Dialysis fluids and local host resistance in patients on continuous ambulatory peritoneal dialysis. Eur J Clin Microbial Infect Dis 1988:7: 368-373.
25. Bos HJ, Vlaandcren K. van der Meulen J. de Veld JC, Oc LP. Bcel-en RHJ: peritoneal macrophages in short dwell time effluent show diminished phagocytosis. Peril Dial Int 1988:8:199-202.
26. Ing BL. Gupta DK. Nawab ZM. Zhou F. Rahaman MA. Daugirdas JT: Suppression of neutrophil superoxide production by conventional peritoneal dialysis solutions. Int J Artif Organs 1988:11:351-354.
27. Moughal NA. McGregor SJ. Brock JH. Briggs JD. Junor BJR: Expression of transferrin receptors by monocytes and peritoneal macrophages from renal failure patients treated by continuous ambulatory peritoneal dialysis. Eur J Clin Invest 1991:21:592-596.
28. Davies SJ., Suassuna J., Ogg CS., Cameron JS: Activation of immunocompetent cells in the peritoneum of patients treated with CAPD. Kidney Int 1989:36:661 —668.
29. Lewis SL, Norris PJ., Holmes CJ: Phenotypic characterization of monocytes and macrophages from CAPD patients. Trans Am Soc Artif Intern Organs l990:36:M575-757.
30. Krane SM. Golding MD: Potential role for interleukin A-1 in fibrosis associated with chronic ambulatory peritoneal dialysis. Blood Purif 1988:6:173-177.
31. Brcborowicz A: Free radicals in peritoneal dialysis: Agents of damage? Périt Dial Int 1992:12:194-198.
32. Bos HJ., Meyer F, de Veld JC., Beel-cn RHJ: Peritoneal dialysis fluid induces change of mononuclear phagocyte proportions. Kidney Int 1989:36:20-26.
33. Vachula M, Aono F., Kubey W., Holmes C: Effect of peritoneal dialysis fluid on mononuclear cell surface receptor expression. J Am Soc Nephrol 1991:2:368.
34. Jörres A., Richter D., Hain H., Gahl G, Muller C., Köttgen E., Mahiout A: Cytokine release from peripheral and peritoneal phagocytes: ElTect of CAPD dialysate. Kidney Int 1990; 37:329.
35. Joncs A. Jörres D. Gahl GM. Kessel M. Muller C. Köttgen E. Serke S. Schulz E. Mahiout A: Leukotriene Bj and tumor necrosis factor from leukocytes: Effect of peritoneal dialysate. Nephron 1991:58:276-282.
36. Douvdevani A. Rapoport J. Konfor-ti A. Zlotnik M. Chaimovitz C: The effect of peritoneal dialysis lluid on cytokine release: Factors involved and time course. Périt Dial lat 1993; 13:112-117.
37. De Fijter CWH. Verbrugh HA. Peters EDJ. Oe PL, Van der Meulcn J. Verhoflf J, Donker AJM: In vivo exposure to the currently available peritoneal dialysis fluids decreases function of peritoneal macrophages in CAPD. Clin Nephrol 1993:39: 75-80.
38. Chaimovitz C: Peritoneal dialysis. Kidney Int 1994:45:1226-1240.
39. Topley N. Mackenzie R. Petersen MM. Beavis MJ. Williams D. Thomas N, Faict D, Pcluso F. Coles GA. Davies M. Williams JD: In vitro testing of a potentially biocompatible continuous ambulatory peritoneal dialysis fluid. Nephrol Dial Transplant 1991:6:574-581.
40. Van Bronswijk H. Verbrugh HA. Bos HJ. Heezius HCJM. van der Meulcn J. Oe LP. Verhof J: Cytotoxic effects of commercial continuous ambulatory peritoneal dialysis fluids and of bacterial cxoproducts on human mésothélial cells in vitro. Périt Dial Int 1989:9:197-202.
41. Holmes CJ: Biocompatibility of peritoneal dialysis solutions. Peril Dial Int 1993:13:88-94.
42. Dobbic JW: Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Périt Dial Int 1992:12:14-27.
43. Miller FN., Nolph KD., Harris PD., Rubin J., Wiegman DL., Joshua IG, Twardowski ZJ. Ghods AJ: Micro-vascular and clinical effects of altered peritoneal dialysis solutions. Kidney Int 1979:15:630-639.
44. Akers JE, Agalloco JP: Aseptic processing - a current perspetive: in Morissey RF, Phillips GB (eds): Sterilization Technology - A Practical Guide for Manufacturers and Users of Health Care Products. New York. Van Nostrand Reinhold. 1993, pp 286-308.